Barclays PLC Cuts Holdings in IDEXX Laboratories, Inc. $IDXX

Barclays PLC trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 211,438 shares of the company’s stock after selling 25,232 shares during the quarter. Barclays PLC owned approximately 0.26% of IDEXX Laboratories worth $143,044,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Beacon Investment Advisory Services Inc. raised its position in shares of IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares in the last quarter. Nordea Investment Management AB raised its position in shares of IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after buying an additional 8,845 shares in the last quarter. NEOS Investment Management LLC boosted its stake in shares of IDEXX Laboratories by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock valued at $19,199,000 after purchasing an additional 13,599 shares in the last quarter. Procyon Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $1,966,000. Finally, Diversified Trust Co. boosted its stake in shares of IDEXX Laboratories by 223.5% in the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after purchasing an additional 2,901 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 1.6%

Shares of NASDAQ IDXX opened at $570.00 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The firm has a market capitalization of $44.96 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 3.07 and a beta of 1.56. The firm has a fifty day simple moving average of $563.07 and a two-hundred day simple moving average of $625.43.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the business earned $2.91 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.